PROCR and COVID-19: In a previously mentioned study on EPCR, researchers found that the inflammatory response and pro-coagulant phenotype induced by immunoglobulins in COVID-19 patients could be suppressed by complement factor 3 inhibitor compstatin and inhibitory αEPCR 1496, suggesting these molecules could also be considered for APS treatment (93).